Sidley represented NeuroFront in its exclusive licensing agreement with Neurolief to develop and commercialize Relivion®, non-invasive medical devices for the treatment of migraines and depression, in Greater China (mainland China, Hong Kong, Macau, and Taiwan) and South Korea.
NeuroFront is a China-based clinical stage neuroscience biotech company with a focus on developing and commercializing innovative neuroscience therapies to address unmet needs and improve patients’ lives in Asia.
The Sidley team was led by partners Ruchun Ji (Shanghai and Palo Alto) and Joshua Hofheimer (Los Angeles and Palo Alto), with the support of associate Longbo Wang (Shanghai).
Sidley provides multidisciplinary services for life sciences clients. We advise clients across the full spectrum of their business lifecycles, ranging from formation, corporate governance, and compliance operations for start-ups to collaboration, licensing, commercialization, and filing in the business development phase, including initial public offerings, equity financings, and bond/note issuances, as well as domestic and cross-border mergers and acquisitions, asset restructuring, equity incentive plans, and privatizations.